Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q2 2023 Earnings Call Transcript

And again, as has been shown from the previous studies, this is a space actually where the power is quite good compared to most neurodegenerative diseases. So, I’d say overall — and again, I encourage people to listen to the webinar where we go into this in a lot more detail. But I’d say overall, we feel very strongly that we have a great trial design, we have a great scientific rationale and that this is a great indication to take AMX0035 into.

Ananda Ghosh: Great. Thanks, very much.

Operator: This will conclude our question-and-answer session. I’ll turn the conference back over to Justin Klee for any closing remarks.

Justin Klee: Well, thank you operator and thank you all for joining us on the call today and for your support. So we hope, you all have a good evening. Thanks for joining us.

Operator: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.